Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) have been given an average recommendation of "Moderate Buy" by the nine ratings firms that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $16.75.

Several research firms recently weighed in on FOLD. Morgan Stanley reissued an "equal weight" rating and issued a $12.00 target price (down from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Cantor Fitzgerald restated an "overweight" rating and issued a $21.00 price target on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. StockNews.com downgraded Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Thursday, February 20th. Finally, Wells Fargo & Company lowered their price target on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a report on Thursday, February 20th.

Remove Ads

Institutional Trading of Amicus Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Virtus Fund Advisers LLC bought a new stake in Amicus Therapeutics in the fourth quarter valued at $29,000. Covestor Ltd grew its position in Amicus Therapeutics by 114.9% during the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock valued at $41,000 after purchasing an additional 2,312 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Amicus Therapeutics during the third quarter valued at approximately $55,000. GF Fund Management CO. LTD. purchased a new position in shares of Amicus Therapeutics in the fourth quarter worth $59,000. Finally, R Squared Ltd bought a new position in Amicus Therapeutics during the 4th quarter valued at about $79,000.

Amicus Therapeutics Trading Down 0.5 %

Shares of Amicus Therapeutics stock traded down $0.04 during trading hours on Monday, hitting $7.91. The company's stock had a trading volume of 814,000 shares, compared to its average volume of 2,522,264. Amicus Therapeutics has a 12 month low of $7.76 and a 12 month high of $12.65. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42. The stock has a 50 day moving average of $9.22 and a 200 day moving average of $9.91. The company has a market capitalization of $2.43 billion, a PE ratio of -43.94, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.